Company news

Allarity Therapeutics, Inc. news in 2026

Allarity Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

November 18, 2026

Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts

November 16, 2026

Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance

November 13, 2026

Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

October 30, 2026

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

September 30, 2026

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

September 28, 2026

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

September 15, 2026

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

September 11, 2026

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

August 14, 2026

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

July 6, 2026

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

June 30, 2026

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

June 18, 2026

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 15, 2026

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 8, 2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

May 5, 2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

April 27, 2026

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

April 21, 2026

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

March 30, 2026

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

March 5, 2026

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

February 18, 2026

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

February 3, 2026

Decks in 2026